menu
    • menu
    [{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"Cosette Pharma","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"JAPAN","productType":"Small molecule","year":"2022","type":"Divestment","leadProduct":"Amlodipine","moa":"L-Type VGCC","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Daiichi Sankyo \/ Cosette Pharmaceuticals","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ Cosette Pharmaceuticals"},{"orgOrder":0,"company":"Zydus Lifesciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"INDIA","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Olmesartan Medoxomil","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Approved","graph3":"Zydus Lifesciences","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Zydus Lifesciences \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Zydus Lifesciences \/ Not Applicable"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"D","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Partnership","leadProduct":"Zilebesiran","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"F. Hoffmann-La Roche","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ F. Hoffmann-La Roche"},{"orgOrder":0,"company":"Alnylam Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Cardiology\/Vascular Diseases","country":"U.S.A","productType":"Large molecule","year":"2024","type":"Not Applicable","leadProduct":"Zilebesiran","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase II","graph3":"Alnylam Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Alnylam Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Alnylam Pharmaceuticals \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Olmesartan

    Menu

    Olmesartan

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Alnylam Presents Positive KARDIA-2 Phase 2 Study Results of Zilebesiran

                            Details : ALN-AGT01 (zilebesiran) investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen in development for the treatment of hypertension in high unmet need populations.

                            Brand Name : ALN-AGT01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            April 07, 2024

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Roche and Alnylam's Kardia-2 Study Shows Blood Pressure Drops with Zilebesiran

                            Details : ALN-AGT01 (zilebesiran) is an investigational, subcutaneously administered RNAi therapeutic targeting angiotensinogen. It is being evaluated in combination with standard of care for hypertension.

                            Brand Name : ALN-AGT01

                            Molecule Type : Large molecule

                            Upfront Cash : Not Applicable

                            March 05, 2024

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            Alnylam Pharmaceuticals

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            DEALS_DEV arrow-down

                            Roche Enters Partnership with Alnylam to Co-Develop and Co-Commercialise RNAi Therapeutic Zilebesiran to Treat...

                            Details : Under the partnership, Roche and Alnylam will co-develop and co-commercialise RNAi therapeutic ALN-AGT01 (zilebesiran), an investigational RNAi therapeutic currently in Phase 2 for the treat hypertension in patients with high cardiovascular risk.

                            Brand Name : ALN-AGT01

                            Molecule Type : Large molecule

                            Upfront Cash : $310.0 million

                            July 24, 2023

                            Lead Product(s) : Zilebesiran,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase II

                            Sponsor : F. Hoffmann-La Roche

                            Deal Size : Undisclosed

                            Deal Type : Partnership

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Zydus Lifesciences

                            India arrow
                            Antibody Engineering
                            Not Confirmed

                            Zydus Lifesciences

                            India arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Olmesartan Medoxomil,Hydrochlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Zydus Receives Final Approval from The USFDA for Olmesartan Medoxomil and Hydrochlorothiazide Tablets

                            Details : A generic combination is approved consisting of olmesartan medoxomil which blocks the vasoconstrictor effects of angiotensin II in vascular smooth muscle and hydrochlorothiazide is a diuretic that inhibits sodium chloride transport in the distal convolut...

                            Brand Name : Benicar HCT-Generic

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 28, 2023

                            Lead Product(s) : Olmesartan Medoxomil,Hydrochlorothiazide

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Daiichi Sankyo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Amlodipine,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Approved

                            Sponsor : Cosette Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            DEALS_DEV arrow-down

                            Daiichi Sankyo to Divest Certain Cardiovascular and Other Legacy Products to Cosette Pharmaceuticals in the Un...

                            Details : The agreement outlines a transition period during which Daiichi Sankyo and Cosette will transfer responsibilities for the manufacture and commercialization of Azor, Benicar, Effient and other products, including quality assurance, pharmacovigilance and r...

                            Brand Name : Azor

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            January 18, 2022

                            Lead Product(s) : Amlodipine,Olmesartan Medoxomil

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Approved

                            Sponsor : Cosette Pharma

                            Deal Size : Undisclosed

                            Deal Type : Divestment

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth